Home › Companies › KURA

Kura Oncology

KURA Lead: Approved 4 Biotech Distilled articles ↓

Metabolic Oncology Small Molecule

Most recent annual filing: 2026-03-05

Pipeline (9 active programs)

KOMZIFTI

ziftomenib

Small Molecule Target: menin, KMT2A, FLT3, NPM1

Acute Myeloid Leukemia Approved oral Kyowa Kirin
Pediatric Acute Leukemia Phase 1 oral Blood Cancer United
Gastrointestinal Stromal Tumor Phase 1 oral

KO-7246

Small Molecule Target: menin

darlifarnib

Small Molecule Target: farnesyl transferase

Renal Cell Carcinoma Phase 1 oral

darlifarnib

KO-2806

Small Molecule Target: farnesyl transferase, KRAS G12C, RHEB, mTORC1

Non-Small Cell Lung Cancer Phase 1 oral Mirati Therapeutics
Colorectal Cancer Phase 1 oral Mirati Therapeutics
Pancreatic Ductal Adenocarcinoma Phase 1 oral Mirati Therapeutics

Discontinued (1)

tipifarnib — Head and Neck Squamous Cell Carcinoma · KURRENT-HN trial completed in Q3 2025; evaluating data generation options for next steps with darlifarnib combination

Biotech Distilled coverage (4)

2026-06-11 UPDATE: Kura Oncology (KURA) — The Binary Prints, Three Days Early
2026-06-02 UPDATE: Kura Oncology (KURA) — The Ven/Aza Arm Gets Its Receipt
2026-05-30 UPDATE: Kura Oncology (KURA) — Subscriber Update
2026-05-15 Kura Oncology (KURA) - Scientific Deep Dive for Ziftomenib and Pipeline Products 🔒 Paid

Articles open on Substack. Some deep dives are subscriber-only.